Dr Mark Treherne

Mark Treherne has 30 years’ experience in the discovery of novel treatments for and the diagnosis of diseases with unmet medical needs. Formerly at Pfizer, he then set up Cambridge Drug Discovery as a co-founder and Chief Executive in 1997, which was sold to BioFocus plc in 2001 and then to Charles River. Since then, helped to raise over £370 million, mostly for early-stage life sciences companies. Now served on the boards of multiple therapeutics, research services, research tools and diagnostics companies worldwide. Worked with teams to out licence therapeutic assets over the last 25 years for upfront payments, milestones and future royalties exceeding £1.5 billion.